Physician profile
Karin Gerberding
NPI 1265849335
$2,356.32
in general payments reported to CMS, 2019-2025
24 companies · $521 in 2025
The $521 reported for 2025 was more than what 87% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $573 · 2022: $501 · 2023: $440 · 2024: $321 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.47 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $494.79 | 2021-2024 | |
| Organon LLC | $267.92 | 2021-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $204.56 | 2021-2025 | |
| Pfizer INC. | $178.63 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $166.82 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $143.71 | 2023-2025 | Veozah, Myrbetriq |
| Agile Therapeutics, INC. | $138.70 | 2021-2023 | Twirla |
| Millicent US INC | $124.44 | 2024-2025 | Femlyv, Femring, Intrarosa |
| Novo Nordisk INC | $120.99 | 2021 | |
| Amgen INC. | $92.58 | 2021-2025 | Evenity |
| Exeltis, USA INC. | $59.40 | 2022-2025 | Slynd |
| Pacira Pharmaceuticals Incorporated | $54.07 | 2023 | Exparel |
| Biogen, INC. | $49.70 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $40.94 | 2024-2025 | Novasure, Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $36.86 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $26.89 | 2021-2022 | |
| Aspira Women'S Health INC | $26.66 | 2022 | |
| Avion Pharmaceuticals | $26.17 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $23.19 | 2024 | |
| Merck Sharp & Dohme LLC | $17.93 | 2021 | |
| Boston Scientific Corporation | $17.36 | 2024 | Advantage System |
| Olympus America INC. | $15.59 | 2025 | Olympus |
| Scynexis, INC. | $15.18 | 2022 | |
| Therapeuticsmd, INC. | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Gerberding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.